摘要
目的:探讨大肠癌患者多药耐药与组织学分级和临床病理学Dukes分期之间的关系。方法:采用逆转录-聚合酶链反应(RT-PCR)的方法检测了60例大肠癌患者肿瘤组织的mdr-1表达水平,同时检测了其中20例大肠癌患者的正常大肠组织作为对照。结果:高、中、低分化大肠癌组织之间mdr-1表达水平具有极显著差异,大肠癌组织和正常大肠组织之间mdr-1表达水平具有极显著差异,Dukes分期的不同期之间mdr-1表达水平无显著差异。结论:临床检测大肠癌患者mdr-1基因的表达,可以预测患者对化疗的敏感性,从而进行有针对性的治疗,使化疗个体化。
Objective: To evaluate the relationship between multidrug resistance of colorectal carcinoma and histological differentiation and Dukes clinicopathological staging. Methods: The expression of multidrug resistance (mdr 1 mRNA) was measured in 60 colorectal carcinoma samples and 20 normal colorectal tissues with RT PCR (reverse transcription polymerase chain reaction). Results: The level of mdr 1 gene expression in colorectal carcinoma appears correlating with the degree of histological differentiation,but not with the Dukes stage of the tumor. The difference of the level of mdr 1 gene expression between colorectal carcinoma and normal colorectal tissues is very remarkable. Conclusion: Measuring the expression of mdr 1 gene in colorectal carcinoma may predict the patients sensitivity to chemotherapy so that one can individualize the chemotherapy protocol for the patient.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1999年第1期39-41,共3页
Chinese Journal of Clinical Oncology
基金
黑龙江省自然科学基金